AIM ImmunoTech Inc. (NYSE AMERICAN: AIM)
$0.40
+0.0310 ( +8.38% ) 247.3K
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Market Data
Open
$0.40
Previous close
$0.37
Volume
247.3K
Market cap
$22.97M
Day range
$0.37 - $0.40
52 week range
$0.31 - $0.75
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Mar 18, 2024 |
4 | Insider transactions | 1 | Mar 18, 2024 |
8-k | 8K-related | 40 | Feb 20, 2024 |
8-k | 8K-related | 16 | Feb 09, 2024 |
8-k | 8K-related | 19 | Jan 25, 2024 |
8-k | 8K-related | 14 | Jan 10, 2024 |
8-k | 8K-related | 12 | Jan 10, 2024 |
4 | Insider transactions | 1 | Nov 27, 2023 |
8-k | 8K-related | 31 | Nov 15, 2023 |
10-q | Quarterly Reports | 66 | Nov 14, 2023 |